Design considerations for aerosol delivery to Children and Infants
Dr Ronan MacLoughlin
(1) Aerogen (2) School of Pharmacy, Royal College of Surgeons, Dublin, Ireland (3) School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland.
Children and infants are not simply small adults and require special consideration when planning aerosol-mediated inhalation drug therapy. Further, the variety of presentations in children and infants is vast, and includes a disparate range that includes ~0.5kg premature infants with respiratory distress syndrome (RDS), term infants with (RSV) infection and older children with complications associated with lung infection or Pulmonary Hypertension as examples. With continual advances in formulation, aerosol generator technology, patient interventions and patient interfaces, several options are now available to both designers of drug/device combination products, and caregivers at the bedside tasked with the selection and use of these products.